Specific inhibition of IL‐6 receptor attenuates inflammatory bone loss in experimental periodontitis

Autor: Luis Fernando Ferreira Oliveira, Michel Reis Messora, Karine Costa, Ana Carolina Aparecida Rivas, Mário Taba, Kleber Tanaka Suzuki, Adriana Luisa Gonçalves de Almeida, Milla Sprone Tavares Ricoldi, Gustavo Henrique Apolinário Vieira
Rok vydání: 2021
Předmět:
Zdroj: Journal of Periodontology. 92:1460-1469
ISSN: 1943-3670
0022-3492
DOI: 10.1002/jper.20-0455
Popis: BACKGROUND Periodontal pathogenesis takes into consideration that disease results from a complex inflammatory immune response. Among the major cytokines related to periodontal damage, interleukin (IL)-6 enhances a cascade of tissue destruction. Tocilizumab (TCZ) is a humanized monoclonal anti-human IL-6 receptor that inhibits IL-6-mediated proinflammatory activity. This study aimed to elucidate whether TCZ inhibits the deleterious effect of ligature-induced periodontitis. METHODS Experimental ligature-induced periodontitis was treated with systemic administration of TCZ intraperitoneally in three different concentration dosages (2 mg/kg, 4 mg/kg, and 8 mg/kg. Euthanasia occurred at 7 and 14 days after the initiation of the study. Local changes in the alveolar bone were measured by bone volume, the ratio of bone volume, and trabecular thickness using microcomputed tomography. Attachment loss and inflammatory infiltrate were evaluated by histology. Immune response was analyzed focusing on the Th17 pattern. RESULTS TCZ inhibited alveolar bone resorption and attachment loss in 7 and 14 days for all dosage groups in comparison to controls (P < 0.05). Besides, TCZ induced lower expression of inflammatory infiltrate (P
Databáze: OpenAIRE
Externí odkaz: